Based on strong evidence that XIAP expression in cancer cells promotes resistance to chemotherapy and radiation as well as elicit anti-cancer immune responses, the past decade has seen development of XIAP-specific targeting using RNA approaches [45,46,47,48,49], pan-IAP peptidomimetics, and small molecule inhibitors [17,19,50,51,52,53]. Here, XIAP is linked to cancer.